OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

If you read between the lines OXBs statement on the 22nd December 2010 looks pretty bullishfast track 5x dosethe start of 5x dose treatment is timed perfectly with the preliminary results in MarchDMC approval to open the second site in the UK at Addenbrookesa Phase II trial of ProSavin could be initiated in the EU/US in 2012 and planning is underway for this stage of the development programmeand all around the very badly timed fundraising?Looks fairly confident action to me!

The study's independent Data Monitoring Committee (DMC) has reviewed the data and supports the Company's proposal to proceed to a 5x dose, facilitated by the enhanced administration technique, in a six-patient cohort. Importantly, the 5x human dose is the allometrically-scaled equivalent (i.e. a dose that is scaled for the difference in brain size between humans and the pre-clinical model) to the highly efficacious pre-clinical dose published in Jarraya et al. Sci Transl Med. 2009 Oct 14;1(2). The DMC also gave its approval to open the second site in the UK at Addenbrookes Hospital, Cambridge, with Dr Roger Barker as Principal Investigator, which will recruit some of the six patients into the 5x dose cohort.

Oxford BioMedica plans to initiate treatment of the 5x dose cohort in Q1 2011. To date, nine patients have been treated at the Henri Mondor Hospital, Paris, with Professor Sthane Palfi as Principal Investigator. The first patient in the 5x dose cohort will be treated in Paris, one month after which subsequent patients can be treated in parallel at both sites which is expected to increase the rate of recruitment and treatment. Results from the first three patients in the 5x dose cohort are expected in mid-2011. Depending on the efficacy seen with the 5x dose, a Phase II trial of ProSavin could be initiated in the EU/US in 2012 and planning is underway for this stage of the development programme.

http://clinicaltrials.gov/ct2/show/NCT00627588?term=prosavin&rank=1

ProSavin still at least 3 years away from production, assuming it gets through Phase II and III.

OXB will either have been taken over by then or have returned to the market for additional funds many times over. Very rarely do tiny Bios ever progress a drug from inception to the shelves.

On occasion the market gets excited about the possibilities of a new drug with a likewise reaction to the SP. AZM were a good example, but still ended up in administration.

Blimey - didn't realise this lot were still around.

cor! what a stinkerooney of a chart ...... i know Toya (of blessed memory) used to follow this carefully ..... i wonder what has become of her?

i sold outta oxb and pym about a year ago at around the same time, not really kept up much just occasional glance at oxb because of how long pharma approvals can take - i need to te view pym also - when i sold it was around the time michael fox foundation was providing some research cash - anyhow sp here looks interesting here now - knew about the potential manufacturing side some time ago but heard that the site and facilities will not be that good more a non preferred cheap option so tended to keep away - anything imminent here or no more than 6 mths away to get excited about - was nearly locked in here once & pym till the 10p / share offer allowed me to recoup losses - just looked up posts above & see pth makes some relevant points and tabasco also - looks like my 6mth hope out the window then - and yep chart none too hot - gla

by the way the mj fox research cash comment last post was ref pym not oxb

Little time to post this weekin Norfolk/Suffolkand have a lot to dobut couldnt miss this biggiecheap as chips!


Acquisition of Manufacturing Facility
Share this article
TIDMOXB

RNS Number : 2988A

Oxford Biomedica PLC

31 January 2011

OXFORD BIOMEDICA ACQUIRES GMP MANUFACTURING FACILITY

-- Support for Oxford BioMedica's five LentiVector(R) technology-based programmes --

-- UK production facility in Oxford to be operational in 2012 --

Oxford, UK - 31 January 2011: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that it has agreed to acquire a manufacturing facility ("the facility") based in Oxford, UK from RecipharmCobra Biologics, the specialist biologics division of Recipharm AB, for a purchase price of GBP1.9 million.

The acquisition and operation of this manufacturing facility is a planned use of proceeds following the Company's recent GBP20 million fundraising which closed on 10 January 2011. The acquisition of the facility is expected to complete by the end of February 2011.

The manufacturing facility will enable Oxford BioMedica to have greater control of the production of its proprietary LentiVector(R) gene delivery technology in order to support five of the Company's clinical programmes. With the ocular products partnered with sanofi-aventis advancing into Phase I/II development during 2011, in addition to the planned progression of ProSavin(R) into a randomised Phase II study for Parkinson's disease in 2012, the facility is expected to deliver long-term operational and financial efficiencies for the Company in comparison to outsourcing processes to a specialist contract manufacturing organisation. This acquisition will also reduce the Company's dependence on a single manufacturing source for its growing clinical portfolio and facilitate the rapid implementation of improved manufacturing processes at increased scale.

The facility totals approximately 16,000 square feet, which includes c. 4,400 square feet in cleanrooms, and is already configured to meet the Company's manufacturing requirements. The facility was previously approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to Good Manufacturing Practice (GMP) standards. Oxford BioMedica anticipates a minimum of 12 months to re-commission the facility which will include the first phase of staff recruitment towards the anticipated fully-operational level of about 35 to 40 staff. The Company estimates an annual running cost of approximately GBP2.2 million per annum for the facility.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "As our ocular programme continues to advance we look forward to the significant growth of our clinical portfolio from two lead products, ProSavin(R) for Parkinson's disease and RetinoStat(R) for "wet" AMD, to five clinical products using our proprietary LentiVector(R) gene delivery technology. Investment in our specialist manufacturing processes will ensure the rapid progression of these five products through Phase II, Phase III and to market. Importantly, this acquisition also provides the opportunity for Oxford BioMedica to become the LentiVector(R) technology supplier of choice for its current and future partners which could provide additional revenues in the coming years."

-Ends-

gibby - PYM is having its agm in London, soon. Will you attend? FWIW I suspect they want more money, hence attracting City types to the AGM (usually the arer in Godmanchester and only the Registrar travels there! HUh).

OXB- SP is taking a time to recover...any ideas? Volumes of Sell outweigh Buys (today 7:1)- ooer that's looking pretty poor.

tabasco - I'm guessing you are reasonably bullish, any comment on current sp? - and did OXB tell us about that Mfr option?
I just don't believe they need it - yet as a LT deal it makes sense, but I don't know what capacity this facility has* - or IF it needs more cash to get it on-line. Was it a good-deal I wonder?
The SP is telling otherwise...

PYM (ditto,) ==pair of smelly eggs - but which is rotten?



*but yr post 31Jan helps.

Hangonthis might help.

http://www.oxfordtimes.co.uk/business/8828490.BioMedica_buys_mothballed_plant/

With OXB eventually recruiting another 35-40 high-tech jobs for their manufacturing plantthey must be extremely confident covering that additional huge costor know more than they are saying? my guess is Sanofi-Aventis have made some guarantees?I believe SA have a trading update next week
This stock is definitely a puntbut I fancy the odds strongly at this 5-6p levelmight prove to be very tastywith a bit of luck?

tabasco - thanks for the link, I wondered this wasn't the old [AIM-]Cobra-plant (now gone away)...got out of that stinker, but their plant is fairly modern I guess.

tabasco, - er, why sanofi? They departed PDQ a while ago and gave OXB 14m (was it?), which I assume has been spent wisely...already.

I'm wondering if OXB has sent a few profs down to Sandwich, where Phizer is shutting shop. Far too expensive to "take-over" but there are bound to be a few who would be prepared to move to Oxford.

That Phizer plant was responsible for Viagra, which is soon off-patent... but some similar research is needed for OXB as I am concerned this Cancer-Co is taking too long to turn any profit....we don't need ideals - - - - - we need "product-sales" and nothing so far.

This puts OXB in the same sad-basket as PYM...who have yet to sell one tin of weight-reduction.......Grr.

Tabasco: thanks for that link to the Oxford Times.

I did hear good things about OXB and ASM while working in Oxford a couple of years back. And yes Cynic: I did used to trade both these but got out of them a long time ago. I'm not tempted to risk any more funds on small biotechs and agree with ptholden that they are very risky businesses. Some do pull through, of course, but there are better places to go fishing I reckon.

Cheers Toya

They are not wasting a lot of time here then?

Oxford Biomedica PLC

09 February 2011

OXFORD BIOMEDICA APPOINTS JAMES CHRISTIE AS NEW HEAD OF MANUFACTURING

with immediate effect.

Just wonder if OXB are being held down by mm's in order for people to close their shortssome large sells going through

CMC
UK AIM Share Bets AIM share bets that remain open will be closed out at the closing price on 11 February 2011

Taken from another thread

Shares Mag 10/2/11 info:-

Gene therapy specialist Oxford Biomedica (OXB)has the funds in place to progress its very promising development pipeline, which includes treatments for a range of diseases, most notably cancer,Parkinsons disease and opthalmological disorders. Positive newsflow over the next 12 months should take the shareprice higher.
Sentiment in the stock was hit byDecembers heavily discounted that saw the Oxford-based firm raise 18.4million net of expenses. It placed 279 mil-lion shares and carried out an open offer of a further 121 million shares at 5p each.
Yet investors can take confidence from that deal. It was not only supported by existing institutional investors but by a number of heavy-hitting money managers who joined the share register for the first time.Gartmore (GRT)now owns 2.2% of the issued capital, Artemis 1.6% and Majedie Asset Management 1.5% respectively.
The money raised added to a year-end cash balance of 12million. It will be put to very good use and should enable the company to meet three key strategic objectives.
First, 8.2 million has been put aside to initiate a Phase II trial for Prosavin, Oxford Biomedicas key drug for a one-shot treatment for Parkinsons. Positive news (22Dec) on low-dose trials on humans found average motor function improvement of 26% with no serious adverse events. Higher, optimum dosage Phase I/II trials on humans started in January, with data available by mid-2011.Positive results should enable Oxford Biomedica to then seek a partner to share in the 50 million costs of stage II trials,planned for the second half of 2012. Chief executive John Dawson explains: We will need to do deals with Prosavin and in order to do them most effectively for shareholders we needed a strong balance sheet. Now we can proceed from a position of strength and structure any deal to share the costs of the trials so as to retain a territory, thereby obtaining a greater share of downstream returns. With any such deal will come upfront revenues and the prospect of future milestone payments and royalties that should be significantly earnings enhancing in the medium term.House broker Singer has calculated Prosavin could reach market by 2017 with the potential to generate sales of 628 million within five years of launch, and there-fore annual income to Oxford Biomedica of 113 million.
Second, the 52.5 million cap is establishing proprietary manufacturing facili-ties following the purchase (31 Jan) of a specialist site at a cost of 1.9 million. This should come onstream by mid-2012 after 2 million in additional investment. This will then provide sufficient capacity for the company to produce clinical products using its proprietary LentiVector gene delivery technology.
Finally, Oxford Biomedicas ocular pro-gramme is also progressing well. In December a US Phase I/II trial of RetinoStat for age-related macular degen-eration began. Results are expected by the first half of 2012 and if successful would see Sanofi-Aventis (SAN:PA)exercise its commercialisation option and trigger an estimated $20 million milestone. This could be a blockbuster and Singer estimates could generate royalty and annual manufacturing income to Oxford Biomedica worth 428 million by 2023.
Singers analyst Shawn Manning estimates the investment required to bring these plans to fruition will take group pre-tax losses up to 8.8 million in 2010 and7.8 million in 2011, as against the 5.1million deficit recorded in 2009. Yet he believes these losses will reduce significantly to just 700,000 loss in 2012.Providing suitable product partners are found Manning believes Oxford Biomedica could be profitable as soon as 2014. His 13p price target implies potential upside of 136%.Gene therapy company has funds in place to support product development.

Hmm, odd that they seem to be waking up again... Maybe it'll be another blinking Blinkx? I can't believe I'm thinking of being tempted back in here!

A very bullish reportThe figures are telephone numbers..and I am not deterred by the time scalesthe higher optimum dosage Phase I/II Prosavin trials on humans started in January data available June/Julyif there is a sniff of success we will have many partnership offers to consider imobetter still with a manufacturing plant in placethe ocular programme and TroVax cancer vaccine we could get taken out pretty quick.I think there is very little risk at these levelsand I dont think you will have to wait that long for a nice paydayjust a view from a lucky thicko?

I dont think 6p will be available much longer?

Make that 7p.the recent buying suggests good news on the way?

Does someone know the patient reaction to first 5x dosing....or is the reported Sanofi-Aventis $1.35 Billion set aside for Eye-Care Acquisitions...ringing bells?